-
Mashup Score: 0Money Matters: 6 financial pitfalls physicians should watch out for - 16 hour(s) ago
“Time and again, we see physicians make avoidable mistakes that hinder or delay their ability to reach their financial goals,” writes Jeff Witz, CFP.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1
Data showed that Non-Hispanic Black and Latinx/Hispanic patients were less likely to receive PSMA-PET imaging than non-Hispanic White patients.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Data presented at #ASCO25 showed racial/ethnic disparities in the use of PSMA-PET imaging in patients with metastatic prostate cancer. #pcsm https://t.co/2CPZrYNbDt
-
-
Mashup Score: 0
Data from the #HOPE4KIDNEY trial is intended to support submission for regulatory clearance of the Edison Histotripsy System.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
The enrollment goal has been met in the pivotal #HOPE4KIDNEY trial, evaluating the safety and effectiveness of the Edison System in destroying renal tumors via the histotripsy procedure. #kcsm https://t.co/71YOBRwIOz
-
-
Mashup Score: 2
According to the authors, the mitomycin/BCG regimen could alleviate some of the burden of the global BCG shortage.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
From #ASCO25: Mitomycin plus BCG showed comparable efficacy & safety to BCG alone in NMIBC. With this regimen requiring less doses of BCG, the authors suggest that it may alleviate some of the burden of the global BCG shortage. @ANZUPtrials #BCGMM https://t.co/JRYqnZWWWa
-
-
Mashup Score: 0
The new drug application is backed by data from the phase 2/3 FRUSICA-2 trial.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
China’s NMPA has accepted a new drug application for sintilimab plus fruquintinib for the second-line treatment of patients with locally advanced or metastatic renal cell carcinoma. #kcsm https://t.co/u90HjWvJpl
-
-
Mashup Score: 3GLP-1 agonist use is rising in men with prostate cancer - 2 day(s) ago
In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
The use of GLP-1 receptor agonists is rising in men with prostate cancer, according to data presented at #ASCO25. | #pcsm https://t.co/ttauIQc5kv
-
-
Mashup Score: 0Live Events - 2 day(s) ago
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
The recent Urology Times® Clinical Forum in Carmel, IN, brought urologists together for real-world NMIBC case discussions led by @reichard_chad. Thanks to all who joined! Interested in future forums? Check our events list: https://t.co/4B943l202S https://t.co/usT9dPgcny
-
-
Mashup Score: 1
The approval of darolutamide in mCSPC was supported by data from the phase 3 ARANOTE trial.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Fred Saad, MD, FRCS, shares his thoughts on the recent #FDA approval of darolutamide in mCSPC and walks through key data that supported the agency’s decision. @chumontreal https://t.co/5KRpCt3iJW
-
-
Mashup Score: 12
ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
From #ASCO25: First-line zanzalintinib in combination with nivolumab showed promising preliminary activity with acceptable tolerability in patients with advanced or metastatic ccRCC. #kcsm @JadChahoud @MoffittNews https://t.co/g6ROjDu6tA
-
-
Mashup Score: 0
According to the authors, these data support the ongoing investigation of zanzalintinib in combination with immune checkpoint inhibitors.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
From #ASCO25: First-line zanzalintinib in combination with nivolumab showed promising preliminary activity with acceptable tolerability in patients with advanced or metastatic ccRCC. #kcsm @JadChahoud @MoffittNews https://t.co/s3d7OSQOwC
-
Jeff Witz, CFP, discusses 6 financial pitfalls that physicians should watch out for. https://t.co/ySXAqwYzpu